MedTrace Logo

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

NCT07426484 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-02-23

No results posted yet for this study

Summary

This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC).

The name of the drug involved in this research study is:

-cosibelimab (a type of an anti-PD-L1 antibody)

Conditions

Interventions

DRUG

Cosibelimab

Anti-PD-L1 antibody, single dose vials, via intravenous (into the vein) infusion per protocol

DRUG

Prednisone

Corticosteroid, per standard of care

DRUG

Sirolimus

mTOR Inhibitor, per standard of care

DRUG

Everolimus

mTOR Inhibitor, per standard of care

Sponsors & Collaborators

Principal Investigators

  • Ann Silk, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2030-12-15
Completion
2032-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07426484 on ClinicalTrials.gov